Clinical trials: Plaque Psoriasis.
Plaque Psoriasis
Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis
This is a randomized, double-blind, placebo-controlled, multicenter clinical trial in participants with moderate-to-severe plaque psoriasis .
- Trial name
- NCT06278350
- Testing
- D-2570
- Where
- China
- Volunteers
- 161 people
- Sponsor
- InventisBio Co., Ltd
Plaque Psoriasis
Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis
This study is a randomized, double-blind, placebo-controlled multicenter clinical trial targeting subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT07130604
- Testing
- D-2570
- Where
- China
- Volunteers
- 390 people
- Sponsor
- InventisBio Co., Ltd
Plaque Psoriasis
A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany
The purpose of this observational study is to describe the effectiveness of deucravacitinib treatment and quality of life in adults with moderate-to-severe plaque psoriasis in routine clinical practice in Germany over a 5-year…
- Trial name
- DELPHIN (NCT06104644)
- Testing
- Deucravacitinib
- Where
- 2 sites in Germany
- Volunteers
- 550 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06108544
- Testing
- TAK-279, Apremilast
- Where
- 217 sites in United States, Argentina and 14 more
- Volunteers
- 1,108 people
- Sponsor
- Takeda
Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis
A Study to evaluate efficacy and safety in subjects with moderate to severe Plaque Psoriasis treated with a TYK2 Inhibitor for 12 weeks
- Trial name
- NCT07234591
- Testing
- Tyk2 inhibitor
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Usynova Pharmaceuticals Ltd.
Chronic Plaque Psoriasis
Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis
This study will assess the use of risankizumab in adult patients with moderate to severe chronic plaque psoriasis and compare risankizumab to other commonly used biologics.
- Trial name
- VALUE (NCT03982394)
- Where
- 302 sites in Argentina, Australia and 19 more
- Volunteers
- 2,759 people
- Sponsor
- AbbVie
Plaque Psoriasis, Healthy Volunteer
A Study of UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis
This study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetic profile, and food effect of UA026 tablets.
- Trial name
- NCT07038720
- Testing
- UA026
- Where
- China
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Usynova Pharmaceuticals Ltd.
Plaque Psoriasis
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06088043
- Testing
- TAK-279, Apremilast
- Where
- 132 sites in United States, Australia and 8 more
- Volunteers
- 693 people
- Sponsor
- Takeda
Plaque Psoriasis
A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis
The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06176768
- Testing
- LY3972406
- Where
- 12 sites in United States
- Volunteers
- 33 people
- Sponsor
- Eli Lilly and Company
Psoriasis, Plaque Psoriasis
Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis
Proof of concept study to assess the safety and tolerability of AX-158 in patients with mild to moderate psoriasis. Patients will be evaluated for a 28-day treatment period with either AX-158 or Placebo and then followed for an…
- Trial name
- NCT05725057
- Testing
- AX-158
- Where
- 6 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- Artax Biopharma Inc
Plaque Psoriasis
A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults
The main aim of this study is to assess treatment satisfaction, quality of life, treatment preference, adherence and convenience, psychosocial effects of scalp psoriasis, sleep quality, and effectiveness, and safety of…
- Trial name
- PRO-SCALP (NCT05811234)
- Testing
- CAL/BDP PAD Cream
- Where
- 37 sites in Germany, Spain and 1 more
- Volunteers
- 291 people
- Sponsor
- Almirall, S.A.
Moderate to Severe Chronic Plaque Psoriasis
Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized, double-blind, active-controlled, parallel-group, multicenter study designed to compare the efficacy, safety, immunogenicity, and PK(Pharmacokinetic) of Bmab 1200 with Stelara in adult patients with moderate…
- Trial name
- STELLAR-2 (NCT05335356)
- Testing
- Stelara, Bmab1200
- Where
- United States
- Volunteers
- 384 people
- Sponsor
- Biocon Biologics UK Ltd
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis
" This study consists of two parts: Part 1 (Dose Escalation): A randomized, double-blind, placebo-controlled phase in which approximately 20 to 30 adult patients with plaque psoriasis will receive the investigational treatment…
- Trial name
- MECAP (NCT07129382)
- Testing
- CS32582 capsule（low dose）, CS32582 capsule（medium dose）, CS32582 capsule（high dose）
- Where
- 11 sites in China
- Volunteers
- 220 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Plaque Psoriasis
A Phase 2 Study of HSK47388 Tablets to Evaluate the Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis
The primary objective of this study is to evaluate the efficacy of multiple-dose HSK47388 versus placebo in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT07158268
- Testing
- HSK47388
- Volunteers
- 220 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Plaque Psoriasis, Psoriatic Arthritis
A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India
The main purpose of this study is to investigate the safety and tolerability of ixekizumab in participants in India with moderate-to-severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA)
- Trial name
- NCT05855967
- Testing
- Ixekizumab
- Where
- 14 sites in India
- Volunteers
- 250 people
- Sponsor
- Eli Lilly and Company
Moderate to Severe Chronic Plaque Psoriasis
This is Comparative Study in Normal Healthy Subjects to Evaluate Pharmacokinetics, Safety, Tolerability of Bmab 1200 -Autoinjector (AI) After Single Subcutaneous Injection (45 mg) in Comparison With Bmab 1200 -Prefilled Syringe (PFS).
This is an open-label, 2-arm parallel-group study in normal healthy subjects to evaluate pharmacokinetics, safety, tolerability of Bmab 1200 -autoinjector (AI) after single subcutaneous injection (45 mg) in comparison with Bmab…
- Trial name
- NCT06738277
- Testing
- Bmab 1200 (Biosimilar Ustekinumab)
- Where
- India
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- Biocon Biologics UK Ltd
Plaque Psoriasis
Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis
This is a multicenter, randomized, double-blind, positive drug parallel-group controlled clinical study in China to evaluate efficacy, safety, tolerability and immunogenicity of HLX03 and adalimumab (Humira) in subjects with…
- Trial name
- NCT03316781
- Testing
- HLX03, adalimumab
- Where
- China
- Volunteers
- 262 people
- Sponsor
- Shanghai Henlius Biotech
Plaque Psoriasis
Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)
This is a long-term, open-label, multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in adults with plaque psoriasis.
- Trial name
- NCT04053387
- Testing
- tapinarof cream, 1%
- Where
- 104 sites in United States, Canada
- Volunteers
- 763 people
- Sponsor
- Organon and Co
Plaque Psoriasis in Children, Plaque Psoriasis in Adolescents
A Clinical Study to Evaluate the Safety and Pharmacokinetics of Topical RSS0393 Ointment in Children and Adolescents With Plaque Psoriasis
This study is to evaluate the safety, tolerability, pharmacokinetics and efficacy of RSS0393 topical ointment in the treatment of plaque psoriasis in children and adolescents.
- Trial name
- NCT07102888
- Testing
- RSS0393 Ointment
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
The objective of this registry is to compare outcomes of risankizumab-exposed pregnancies with those of pregnancies that were not exposed to risankizumab among women with plaque psoriasis, psoriatic arthritis (PsA), Crohn's…
- Trial name
- NCT04846959
- Testing
- Risankizumab, Comparator
- Where
- 2 sites in United States
- Volunteers
- 818 people
- Sponsor
- AbbVie